Immuneering Corp (IMRX)vsBeOne Medicines AG (ONC)
IMRX
Immuneering Corp
$3.67
-3.17%
HEALTHCARE · Cap: $243.51M
ONC
BeOne Medicines AG
$415.96
-0.96%
HEALTHCARE · Cap: $46.30B
Smart Verdict
WallStSmart Research — data-driven comparison
BeOne Medicines AG generates 1451976603% more annual revenue ($6.61B vs $455). ONC leads profitability with a 13.9% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 70/100 (B-).
IMRX
Avoid26
out of 100
Grade: F
ONC
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IMRX.
Margin of Safety
+81.0%
Fair Value
$1845.68
Current Price
$415.96
$1429.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 33.8% year-over-year
Earnings expanding 212.5% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Strong operational efficiency at 22.2%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Trading at 8.2x book value
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : IMRX
The strongest argument for IMRX centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 33.8% demonstrates continued momentum. PEG of 0.82 suggests the stock is reasonably priced for its growth.
Bear Case : IMRX
The primary concerns for IMRX are EPS Growth, Market Cap, Profit Margin.
Bear Case : ONC
The primary concerns for ONC are Price/Book, P/E Ratio, Altman Z-Score. A P/E of 52.2x leaves little room for execution misses.
Key Dynamics to Monitor
IMRX profiles as a value stock while ONC is a growth play — different risk/reward profiles.
ONC carries more volatility with a beta of 0.63 — expect wider price swings.
ONC is growing revenue faster at 33.8% — sustainability is the question.
ONC generates stronger free cash flow (474M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (70/100 vs 26/100) and 33.8% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Immuneering Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its proprietary drug discovery platforms. Leveraging sophisticated bioinformatics and machine learning, the company focuses on identifying and refining drug candidates that selectively intervene in pivotal biological pathways, thereby enhancing efficacy and reducing toxicity. With a robust pipeline of novel therapies and strategic alliances, Immuneering is well-positioned to thrive in the rapidly evolving domains of personalized medicine and targeted oncology, offering significant investment opportunities for institutional investors.
BeOne Medicines AG
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?